Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Respiratory Syncytial Virus (RSV): early-phase trial registry

2 of 12 indexed Respiratory Syncytial Virus (RSV) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 2 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Respiratory Syncytial Virus (RSV): 12 US clinical trials tracked, 2 recruiting.

Respiratory Syncytial Virus (RSV) is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 2 of these trials.

Enrollment posture brief

Registry condition respiratory-syncytial-virus-rsv

OPEN 2 | RECR 17% | LATE 2 | EARLY 5 | RANK #1429 | SPON 2

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Respiratory Syncytial Vi (th…17%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV) lists 2 open slots (17% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Respiratory Syncytial Virus (RSV) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Respiratory Syncytial Virus (RSV) is recruiting below its size-band peers.

    2 of 12 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Respiratory Syncytial Virus (RSV) research.

    Pfizer accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Respiratory Syncytial Virus (RSV) enrolment sits around 363 participants.

    Median target enrolment is 363 among the 12 trials that report a genuine target (sentinel values excluded). 3 of those (25%) plan for fewer than 100 participants.

  4. Respiratory Syncytial Virus (RSV) splits between interventional and observational designs.

    7 interventional and 5 observational studies make up this index (58.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22Phase 31Phase 41

Open and recent trials

12 total, page 1 of 1

RECRUITING 2,062 participants

RSV Vaccine Pregnancy Registry

CorEvitas

NCT06521944

RECRUITING Phase 2 170 participants

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

Johns Hopkins University

NCT07050732

ACTIVE NOT RECRUITING 39,456 participants

Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

Pfizer

NCT07249320

ACTIVE NOT RECRUITING 300 participants

Transplacental Transmission of RSV (TTRSV)

Tulane University

NCT05443607

ACTIVE NOT RECRUITING Phase 1 75 participants

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

Immorna Biotherapeutics

NCT06564194

ACTIVE NOT RECRUITING Phase 4 14 participants

Systems Biological Analysis of Immune Responses to RSV Vaccine

Emory University

NCT07185399

COMPLETED 18,157 participants

Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections

Evidation Health

NCT06207929

COMPLETED Phase 3 11,850 participants

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Novavax

NCT02608502

COMPLETED 1,642 participants

Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer

IQuum

NCT02067286

COMPLETED Phase 1 363 participants

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

MedImmune

NCT02289820

COMPLETED Phase 1 128 participants

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

Pfizer

NCT05900154

COMPLETED Phase 2 99 participants

A Study to Evaluate EDP 938 Regimens in Children With RSV

Enanta Pharmaceuticals

NCT04816721

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2
Phase 3 1
Phase 4 1

Top Sponsors

Pfizer 2 trials
IQuum 1 trials
Evidation Health 1 trials
Novavax 1 trials
MedImmune 1 trials
CorEvitas 1 trials
Emory University 1 trials

Named interventions

Most-linked intervention names on Respiratory Syncytial Virus (RSV) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Other
2 trials
IIV Biological
1 trials
MEDI7510 Biological
1 trials
EDP-938 Drug
1 trials
Phosphate Buffer Placebo Biological
1 trials
RSV-F Vaccine Biological
1 trials
RSVpreF 60 µg Biological
1 trials
RSVpreF 120 µg Biological
1 trials

US sites by state

Facility locations filed on Respiratory Syncytial Virus (RSV) trials. A trial with sites in several states counts in each.

Louisiana 5 trials
Florida 5 trials
California 4 trials
Texas 3 trials
North Carolina 3 trials
Georgia 3 trials
Tennessee 2 trials
Ohio 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Respiratory Syncytial Virus (RSV) page

12 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Respiratory Syncytial Virus (RSV) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Pfizer sponsors the most Respiratory Syncytial Virus (RSV) trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Respiratory Syncytial Virus (RSV) condition card totals 12 registered trials; most-linked intervention Placebo; top US site state Louisiana. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.